IL28164A - Substituted ammonium basic addition salts of ribonucleic acid and their preparation - Google Patents
Substituted ammonium basic addition salts of ribonucleic acid and their preparationInfo
- Publication number
- IL28164A IL28164A IL28164A IL2816467A IL28164A IL 28164 A IL28164 A IL 28164A IL 28164 A IL28164 A IL 28164A IL 2816467 A IL2816467 A IL 2816467A IL 28164 A IL28164 A IL 28164A
- Authority
- IL
- Israel
- Prior art keywords
- ribonucleic acid
- acid
- disodium
- novel
- ethanol
- Prior art date
Links
- 229920002477 rna polymer Polymers 0.000 title claims description 36
- 150000003839 salts Chemical class 0.000 title claims description 25
- 150000003863 ammonium salts Chemical class 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 10
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
- 235000003704 aspartic acid Nutrition 0.000 claims description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 6
- 238000006386 neutralization reaction Methods 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 5
- WTZNRJJGOVFIBC-QTNFYWBSSA-N [Na].[Na].N[C@@H](CCC(=O)O)C(=O)O Chemical compound [Na].[Na].N[C@@H](CCC(=O)O)C(=O)O WTZNRJJGOVFIBC-QTNFYWBSSA-N 0.000 claims description 4
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims description 2
- 229960002887 deanol Drugs 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims 3
- 150000003973 alkyl amines Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 15
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 11
- 239000000243 solution Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000007334 memory performance Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- UIJPWDSKPZLJAN-UHFFFAOYSA-N 2-(1,4-dioxan-2-yl)ethanol Chemical compound OCCC1COCCO1 UIJPWDSKPZLJAN-UHFFFAOYSA-N 0.000 description 1
- 241000947840 Alteromonadales Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036649 mental concentration Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55971266A | 1966-06-23 | 1966-06-23 | |
| US56092466A | 1966-06-23 | 1966-06-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL28164A true IL28164A (en) | 1971-11-29 |
Family
ID=27072136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL28164A IL28164A (en) | 1966-06-23 | 1967-06-20 | Substituted ammonium basic addition salts of ribonucleic acid and their preparation |
Country Status (13)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE755361A (fr) * | 1969-08-28 | 1971-03-01 | Newport Pharmaceuticals | Derives de l'inosine |
| GB1458586A (en) * | 1974-01-29 | 1976-12-15 | Beecham Group Ltd | Antiviral complexes of double stranded rna and its derivatives |
| FR2260331B1 (enrdf_load_stackoverflow) * | 1974-02-08 | 1978-01-13 | Mauvernay Centre Europ Rech | |
| JPH0669953B2 (ja) * | 1985-08-16 | 1994-09-07 | 日産化学工業株式会社 | 脳脊髄系神経栄養剤 |
| US5091432A (en) * | 1990-03-28 | 1992-02-25 | Glasky Alvin J | 9-substituted hypoxanthine bi-functional compounds and their neuroimmunological methods of use |
| CZ380296A3 (cs) * | 1994-07-25 | 1998-01-14 | Alvin J. Glasky | Léčivo pro dlouhodobou modifikaci savčí neurální aktivity, léčení neurologických chorob, indukci dlouhodobých změn membránového potenciálu neuronů a jiné účely |
| US5447939A (en) * | 1994-07-25 | 1995-09-05 | Glasky; Alvin J. | Carbon monoxide dependent guanylyl cyclase modifiers and methods of use |
| US5801184A (en) * | 1994-07-25 | 1998-09-01 | Glasky; Alvin J. | Carbon monoxide dependent guanylyl cyclase modifiers and methods of use |
| US6338963B1 (en) | 1994-07-25 | 2002-01-15 | Neotherapeutics, Inc. | Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis |
| US6407237B1 (en) | 2001-02-21 | 2002-06-18 | Neotherapeutics, Inc. | Crystal forms of 9-substituted hypoxanthine derivatives |
| US6849735B1 (en) * | 2000-06-23 | 2005-02-01 | Merck Eprova Ag | Methods of synthesis for 9-substituted hypoxanthine derivatives |
| ATE499103T1 (de) | 2000-07-07 | 2011-03-15 | Spectrum Pharmaceuticals Inc | Verfahren zur behandlung von arzneimittelinduzierter peripherer neuropathie und verwandten krankheitsformen |
| US6759427B2 (en) | 2001-04-20 | 2004-07-06 | Spectrum Pharmaceuticals, Inc. | Synthesis and methods of use of tetrahydroindolone analogues and derivatives |
| US20030055249A1 (en) * | 2001-07-17 | 2003-03-20 | Fick David B. | Synthesis and methods of use of pyrimidine analogues and derivatives |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3068222A (en) * | 1962-12-11 | Trifluoromethyl substituted dibenzxze- | ||
| US3070606A (en) * | 1962-12-25 | Xchxn | ||
| US1678429A (en) * | 1926-08-25 | 1928-07-24 | Soc Of Chemical Ind | Organic gold compounds and process of making same |
| FR769M (enrdf_load_stackoverflow) * | 1960-11-25 | 1961-08-28 | ||
| GB1083911A (en) * | 1964-01-13 | 1967-09-20 | Chugai Pharmaceutical Co Ltd | Adenosine triphosphate salts of l-ornithine and process for preparing the same |
| US3326892A (en) * | 1965-04-16 | 1967-06-20 | Irwin I Lubowe | Allantoin sodium ribonucleinate |
-
1966
- 1966-06-23 US US559712A patent/US3484521A/en not_active Expired - Lifetime
- 1966-06-23 US US560924A patent/US3438968A/en not_active Expired - Lifetime
-
1967
- 1967-05-29 ES ES341109A patent/ES341109A1/es not_active Expired
- 1967-06-03 GR GR670133409A patent/GR33409B/el unknown
- 1967-06-07 SE SE08027/67A patent/SE357561B/xx unknown
- 1967-06-13 NL NL6708204A patent/NL6708204A/xx unknown
- 1967-06-13 CH CH832667A patent/CH487166A/de not_active IP Right Cessation
- 1967-06-15 GB GB27716/67A patent/GB1167993A/en not_active Expired
- 1967-06-16 DE DE19671695278 patent/DE1695278A1/de active Pending
- 1967-06-20 IL IL28164A patent/IL28164A/en unknown
- 1967-06-20 BE BE700231D patent/BE700231A/xx unknown
- 1967-06-21 DK DK320867AA patent/DK122670B/da unknown
- 1967-06-22 NO NO168704A patent/NO125632B/no unknown
- 1967-06-23 FR FR111727A patent/FR6729M/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| SE357561B (enrdf_load_stackoverflow) | 1973-07-02 |
| DE1695278A1 (de) | 1970-09-17 |
| US3438968A (en) | 1969-04-15 |
| CH487166A (de) | 1970-03-15 |
| NO125632B (enrdf_load_stackoverflow) | 1972-10-09 |
| NL6708204A (enrdf_load_stackoverflow) | 1967-12-27 |
| BE700231A (enrdf_load_stackoverflow) | 1967-12-01 |
| DK122670B (da) | 1972-03-27 |
| ES341109A1 (es) | 1968-10-01 |
| GB1167993A (en) | 1969-10-22 |
| GR33409B (el) | 1967-11-30 |
| FR6729M (enrdf_load_stackoverflow) | 1969-02-24 |
| US3484521A (en) | 1969-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1544190A3 (ru) | Способ получени тиазоло [4,5-с] хинолина или его кислотно-аддитивных солей | |
| IL28164A (en) | Substituted ammonium basic addition salts of ribonucleic acid and their preparation | |
| US3925357A (en) | ' -sulfobenzylpenicillin salt | |
| US3703542A (en) | Hydroxamic acid derivatives of 1-amino-cyclohexanecarboxylic acid | |
| RU2080114C1 (ru) | Препарат для лечения туберкулеза | |
| US4939164A (en) | Strontium salt | |
| RU2084449C1 (ru) | 1-бензил-2-оксотриптамин гидрохлорид и его производные, обладающие гепатозащитной активностью | |
| NO168704B (no) | Analogifremgangsmaate for fremstilling av di-t-butylfenylalkyl og benzylethere. | |
| DE3212817C2 (enrdf_load_stackoverflow) | ||
| DE1809119C3 (de) | Infarktprophylaktikum | |
| DE69626548T2 (de) | Macrocyclische verbindungen die aus kohlensuboxi-gruppen besteht | |
| EP0335745A1 (en) | Process for producing pyrid-4-ones | |
| DE2136067C3 (de) | 3-Fluor-D-alanin, 3-Fluor-D-alanin-2-d, deren Salze und diese Verbindungen enthaltende Arzneimittel | |
| EP1669357A8 (en) | Substance which exhibits antiviral and antibacterial activity and is based on derivatives of 2,8-dithioxo-1h-pyrano[ 2,3-d,6,5-d'] dipyrimidine and 10-aza-analogue thereof | |
| GB2044265A (en) | Adenosine Triphosphate Metal Complexes, Processes for Their Preparation and Pharmaceutical Compositions Containing Them | |
| RU2268267C1 (ru) | Комплексы пектинового биополимера с дикарбоновыми кислотами и способ их получения | |
| KR860000450B1 (ko) | α-6-데옥씨-5-하이드록씨 테트라 싸이클린과 소듐 테트라메타포스 페이트의 수용성 복합체의 제조방법 | |
| US4518611A (en) | 2-Furylbutyrolactone modulation of the immune system in mammals | |
| RU2077339C1 (ru) | Иммуностимулятор | |
| EP0123446A1 (en) | 2-Furylbutyrolactone derivatives, their preparation, compositions containing them, and their use for the modulation of the immune system in mammals | |
| SU1069626A3 (ru) | Способ получени 3 @ ,4, @ 5 @ -триметоксиьензоата производных аповинкаминола или их солей | |
| DE1816097A1 (de) | Salze der Orotsaeure | |
| DE2908032A1 (de) | Acetale und hemiacetale von aminoaldehyden und diese enthaltende therapeutische zubereitungen | |
| RU2471787C1 (ru) | Никотиноилгидразон димефосфона, обладающий противотуберкулезной активностью | |
| Davis et al. | Synthesis and microbiological properties of some substituted derivatives of 3-amino-3, 4-dihydrocarbostyril |